Skip to main content
logo
Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.660
-0.010 (-0.60%)
At close: Jun 10, 2026, 4:00 PM EDT
1.622
-0.038 (-2.30%)
After-hours: Jun 10, 2026, 4:29 PM EDT

Inhibikase Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
---0.260.123.1
Revenue Growth (YoY)
---111.03%-96.02%343.92%
Gross Profit
---0.260.123.1
Selling, General & Admin
25.6823.5611.386.736.226.51
Research & Development
30.1229.7917.2113.6212.0411.36
Other Operating Expenses
0.581.37----
Total Operating Expenses
56.3854.7228.5920.3518.2517.87
Operating Income
-55.22-51.97-28.59-20.09-18.13-14.77
Interest Income
2.83.721.071.060.07-0.02
Other Non-Operating Income (Expense)
1.46-----
Total Non-Operating Income (Expense)
4.263.721.071.060.07-0.02
Pretax Income
-50.96-48.26-27.52-19.03-18.05-14.79
Net Income
-50.96-48.26-27.52-19.03-18.05-14.79
Net Income to Common
-50.96-48.26-27.52-19.03-18.05-14.79
Shares Outstanding (Basic)
1199824643
Shares Outstanding (Diluted)
1199824643
Shares Change (YoY)
167.38%314.60%293.35%42.74%39.15%121.72%
EPS (Basic)
-0.43-0.49-1.16-3.16-4.28-4.86
EPS (Diluted)
-0.43-0.49-1.16-3.16-4.28-4.86
Free Cash Flow
-35.74-27.8-19.15-18.1-17.59-14.3
Free Cash Flow Per Share
-0.30-0.28-0.81-3.00-4.17-4.71
Gross Margin
---100.00%100.00%100.00%
Operating Margin
----7711.98%-14686.20%-476.23%
Profit Margin
----7304.73%-14625.90%-476.88%
FCF Margin
----6947.87%-14253.40%-461.10%
EBITDA
-55.17-51.91-28.56-19.91-18.12-14.77
EBITDA Margin
----7643.88%-14680.70%-476.23%
EBIT
-55.22-51.97-28.59-20.09-18.13-14.77
EBIT Margin
----7711.98%-14686.20%-476.23%
SEC Filings: 10-K · 10-Q